Valneva Ixiaro Japanese Encephalitis Vaccine For Travelers

Valneva Ixiaro helps protect adults and children traveling to parts of Asia and the Pacific where Japanese encephalitis is a risk, with use supported by FDA approval for the US market.

Valneva Ixiaro Japanese encephalitis vaccine is a travel vaccine used to help protect adults and children who visit regions where Japanese encephalitis virus is present, including parts of Asia and the Western Pacific, and it is licensed for use in the United States by the FDA FDA, 01/24/2024.

As of: 06/06/2026 | Reading time: approx. 8 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Valneva Ixiaro Japanese encephalitis vaccine
• Category: Inactivated travel vaccine
• Brand/Manufacturer: Valneva
• Primary Use Cases: Prevention of Japanese encephalitis in travelers
• Availability: Prescription vaccine available in the United States
• Core Markets: United States, Europe, Asia-Pacific travel markets

What Valneva Ixiaro Japanese Encephalitis Vaccine Is and How It Works

Valneva Ixiaro Japanese encephalitis vaccine is an inactivated, adsorbed vaccine designed to help the immune system build protection against Japanese encephalitis virus, a mosquito-borne infection found in parts of Asia and the Western Pacific CDC, 02/15/2024.

The vaccine contains inactivated Japanese encephalitis virus grown in cell culture and purified, so it cannot cause the disease but can stimulate an immune response that produces antibodies against the virus, which is why it is used ahead of travel to at-risk areas FDA, 01/24/2024.

Health authorities describe Japanese encephalitis as a potentially severe illness that can lead to brain inflammation, with a higher risk of complications in some patients, so preventive vaccination is considered an important measure for certain travelers who will spend extended time outdoors or in rural areas in endemic regions CDC, 03/10/2024.

Why Valneva Ixiaro Japanese Encephalitis Vaccine Matters for US Consumers and Industry

For US travelers heading to countries where Japanese encephalitis is present, Valneva Ixiaro Japanese encephalitis vaccine offers an FDA-licensed option that clinicians can prescribe and administer as part of pre-travel consultations in the United States CDC, 04/05/2024.

Travel clinics, hospital-based travel medicine centers, and some larger primary care practices in the US typically integrate Ixiaro into broader travel protection plans that may also include routine vaccines, hepatitis A and B vaccines, and counseling on insect bite avoidance, reflecting its role in a comprehensive preventive approach CDC, 01/02/2024.

Because Japanese encephalitis risk is higher for travelers staying for longer periods in rural or agricultural regions, especially during mosquito season, US clinicians often use Ixiaro primarily for expatriates, long-term travelers, and certain business travelers whose work takes them to these environments CDC, 02/20/2024.

Valneva Ixiaro Japanese Encephalitis Vaccine in the US and Global Market

Valneva Ixiaro Japanese encephalitis vaccine sits within a specialized segment of the travel vaccine market, and it is one of the inactivated Japanese encephalitis vaccines available internationally for protection of travelers and certain residents in endemic countries EMA, 11/30/2023.

In the United States, demand for Japanese encephalitis vaccination is closely tied to travel volume to affected regions in Asia and the Western Pacific, which tends to rise and fall with broader international travel patterns, regional business ties, and tourism trends reported for those destinations CDC, 02/20/2024.

Globally, Valneva positions Ixiaro as part of its travel vaccine portfolio alongside vaccines against other infectious diseases, and the product is offered in multiple markets with regulatory approvals from agencies such as the FDA in the US and the EMA in Europe, reflecting its international scope Valneva, 03/18/2024.

• Inactivated Japanese encephalitis vaccine for travelers
• Used in adults and children following local prescribing information
• Administered as an injection before potential exposure in endemic areas
• Available in the United States through travel medicine providers

Frequently Asked Questions About Valneva Ixiaro Japanese Encephalitis Vaccine

Who should consider Valneva Ixiaro Japanese encephalitis vaccine before travel?
Travel health authorities state that vaccination is especially relevant for travelers who will spend longer periods in rural or agricultural areas in countries where Japanese encephalitis is present, or who engage in extensive outdoor activities during transmission season CDC, 02/20/2024.

How is Valneva Ixiaro Japanese encephalitis vaccine typically given?
Health guidance indicates that the vaccine is administered as an intramuscular injection according to an approved dosing schedule described in official product information, with timing that allows the immune system to respond before possible exposure in endemic regions FDA, 01/24/2024.

Is Valneva Ixiaro Japanese encephalitis vaccine available for children in the United States?
Regulatory and clinical information reports that Ixiaro is approved for use in children as well as adults, with age-specific dosing guidance outlined in the prescribing information that clinicians follow when vaccinating pediatric travelers from the United States Valneva, 03/18/2024.

Valneva SE is the company behind the Ixiaro Japanese encephalitis vaccine, and it focuses on developing and marketing vaccines for infectious diseases across multiple international markets.

Valneva SE is listed in Europe and is associated with the ISIN FR0013280286, which identifies the issuer in international securities and regulatory systems.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.